Revium Recovery Inc (RVRC PINK) stock market data APIs
$0.5182
0(0%)
as of December 12, 2025
Try our APIs with
free plan!
Revium Recovery Inc Financial Data Overview
Price chart is built with
Anychart
Revium Rx, a pre-clinical stage biopharmaceutical company, develops nano-liposomal particles (NLP) based pharmaceutical candidates. It develops nanoparticles-based formulation of a potent antibiotic; novel adjuvant for cancer therapies: and novel immunization based on liposomal protein-loaded technology. The company was formerly known as Revium Recovery Inc. and changed its name to Revium Rx. in December 2024. Revium Rx was incorporated in 1997 and is based in Herzliya, Israel.
Prev. Close
0.5182
Open
0.5182
High
0.5182
Low
0.5182
52 wk Range
0.4011-1
Market Cap
31 579 K
Shares Outstanding
60 729 K
Revenue
11 393
EPS
-0.0104
Beta
-1.112
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Revium Recovery Inc data using free add-ons & libraries
Get Revium Recovery Inc Fundamental Data
Revium Recovery Inc Fundamental data includes:
- Net Revenue: 11 393
- EBITDA: -3 839 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Revium Recovery Inc News
New
Undiscovered Gems in Europe for November 2025
As European markets navigate a landscape marked by cooling sentiment on artificial intelligence and mixed economic indicators, the pan-European STOXX Europe 600 Index has shown resilience with a 1.77%...
Three European Stocks That May Be Priced Below Their Estimated Value
As European markets experience a notable upswing, with the pan-European STOXX Europe 600 Index and major national indexes showing gains, investors are increasingly on the lookout for opportunities tha...
Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections
TEL AVIV, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and ...
RVRC Holding Q4 2024/25 slides: modest growth amid challenging market conditions
Introduction & Market Context RVRC Holding AB (STO:RVRC) presented its Q4 and full-year 2024/25 results on August 12, 2025, highlighting the outdoor apparel company’s performance in what management...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
